Neutralizing Antibodies Against Rift Valley Fever Virus: Current Status and Advances
Vaccines · 29.05.2026 · 14 (6) · 484
DOI: 10.3390/vaccines14060484 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 29.05.2026. Verfasst von Binjie Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Student Brigade, School of Basic Medicine, Air Force Medical University: Fourth Military Medical University, Xi'an 710032, China. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Air Force Medical University.
Abstract (Originalsprache)
Background
Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen that has caused repeated epidemics across Africa and the Arabian Peninsula, posing a severe and growing threat to public health and livestock. Infection in ruminants causes high neonatal mortality and catastrophic abortion storms; human disease ranges from self-limiting febrile illness to hemorrhagic fever, encephalitis, and permanent blindness. No licensed human vaccines or specific antiviral therapeutics are available, creating an urgent unmet medical need.
Methods
We systematically reviewed the peer-reviewed literature on RVFV neutralizing antibodies (NAbs), extracting and synthesizing data on antibody sources, epitope specificity, in vitro neutralizing potency, in vivo protective efficacy, and molecular mechanisms of action.
Results
A growing body of work has identified potent NAbs from immunized rodents, rabbits, alpacas, non-human primates, and convalescent patients. These NAbs predominantly target the Gn and Gc envelope glycoproteins. Their mechanisms include blocking host receptor (LRP1) binding, preventing the pH-dependent conformational rearrangement of the Gn–Gc complex, and directly inhibiting viral membrane fusion. Lead candidates, such as RVFV-268 and RVFV-140, achieve sub-nanogram neutralization and confer robust protection in rodent models against lethal challenge, aerosol exposure, and vertical transmission. Bispecific antibodies and combination strategies further enhance potency and the genetic barrier to viral escape.
Conclusions
Substantial progress has illuminated the epitope landscape and neutralization mechanisms of RVFV, yielding promising clinical candidates. Translational challenges remain, including viral immune escape, antibody thermostability, and the need for rigorous preclinical evaluation. Future efforts should prioritize structure-guided engineering, rational antibody combinations, and testing in clinically predictive animal models.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Student Brigade, School of Basic Medicine, Air Force Medical University: Fourth Military Medical University, Xi'an 710032, China.
- Department of Microbiology, School of Basic Medicine, Air Force Medical University: Fourth Military Medical University, Xi'an 710032, China.
ORCID-Profile: Wei Ye
Förderung
- National Natural Science Foundation of China
- Air Force Medical University
Zitieren
APA
Wu, B., Sun, Y., Wang, Y., Wang, Y., Han, Y., Wang, Y., & Ye, W. (2026). Neutralizing Antibodies Against Rift Valley Fever Virus: Current Status and Advances. Vaccines, 14(6), 484. https://doi.org/10.3390/vaccines14060484
Vancouver
Wu B, Sun Y, Wang Y, Wang Y, Han Y, Wang Y, et al. Neutralizing Antibodies Against Rift Valley Fever Virus: Current Status and Advances. Vaccines. 2026;14(6):484. doi:10.3390/vaccines14060484
BibTeX
@article{Wu2026,
author = {Wu, Binjie and Sun, Yuhan and Wang, Yang and Wang, Ye and Han, Yuyang and Wang, Yuan and Ye, Wei},
title = {Neutralizing Antibodies Against Rift Valley Fever Virus: Current Status and Advances},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {6},
pages = {484},
doi = {10.3390/vaccines14060484}
}
EUVIMED